Recovery of <sup>177</sup>Lu from Irradiated HfO<sub>2</sub> Targets for Nuclear Medicine Purposes
A new method of production of one of the most widely used isotopes in nuclear medicine, <sup>177</sup>Lu, with high chemical purity was developed; this method includes irradiation of the HfO<sub>2</sub> target with bremsstrahlung photons. The irradiated target was dissolved i...
Main Authors: | Andrey G. Kazakov, Taisya Y. Ekatova, Julia S. Babenya, Sergey S. Belyshev, Vadim V. Khankin, Alexander A. Kuznetsov, Sergey E. Vinokurov, Boris F. Myasoedov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/10/3179 |
Similar Items
-
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021-11-01) -
Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01) -
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021-12-01) -
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022-08-01) -
Quality Assurance Investigations and Impurity Characterization during Upscaling of [<sup>177</sup>Lu]Lu-PSMA<sup>I&T</sup>
by: Stefan Schmitl, et al.
Published: (2023-11-01)